Overcoming the Challenges of Treating Taxane/Anthracycline-Resistant Breast Cancer: New Therapeutic Strategies CME

Sandra M. Swain, MD; Andrew D. Seidman, MD; Linda T. Vahdat, MD Author Information and Disclosures

Release Date: March 14, 2008; Valid for credit through March 14, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

The content of this activity was developed by education | outcomes | science and the faculty, and was recorded on January 30, 2008, in Washington, DC.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 education | outcomes | science.
BMS
Learning Objectives
After participating in this activity, the learner should be better able to:
  1. Understand the negative impact of drug resistance with anthracyclines or taxanes on patient outcomes;
  2. Increase their knowledge on the latest clinical trials and updates from major medical congresses:
    1. Safety and efficacy of novel treatment options that can overcome or evade resistance in breast cancer;
    2. Benefits and limitations of emerging treatments for patients with taxane-resistant breast cancer:
    3. Novel strategies to improve outcomes in refractory patients.
Author Disclosures
Sandra M. Swain, MD – Chair
Disclosure: Advisor/Consultant: Genentech, Roche, Sanofi-Aventis

Andrew D. Seidman, MD
Disclosure: Dr. Seidman has reported no relevant financial relationships with commercial interests.

Linda T. Vahdat, MD
Disclosure: Dr. Vahdat has reported no relevant financial relationships with commercial interests.

The staff of education | outcomes | science involved with this activity have reported no relevant financial relationships with commercial interests.

Among methods we use to resolve the potential for conflicts of interest in our activities are the signing of the AMA Attestation Form by all planners and faculty, input from learners through an evaluation form pertaining to perception of commercial bias, and the use of independent content reviewers. This educational content was fully peer-reviewed by Susana M. Campos, MD, MPH who disclosed the following financial relationships with commercial interests:

Susana M. Campos, MD, MPH
Disclosure: Speaker: Genentech, Lilly, Pfizer.
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Medical Association has determined that non–US-licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

This activity is provided free of charge to participants.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.